Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

BioDiem granted European patent for antimicrobial drug

Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.

7 Aug 2012

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

BioDiem recently signed a collaborative agreement with The Royal Melbourne Institute of Technology (RMIT) for the development of non-influenza vaccines using BioDiem’s proprietary live attenuated influenza virus (LAIV) technology.

7 Aug 2012

Boric acid treatment equals best practice for otitis media

Study findings show that a single application of boric acid powder followed by external auditory canal irrigation is as effective as topical ciprofloxacin eardrops for treating active chronic otitis media.

6 Aug 2012

Aquapharm discovers new antibiotic compound against multi-drug resistant bacteria

A significant discovery in the development of next-generation antibiotics has been made by Scottish biotechnology company Aquapharm.

6 Aug 2012

Shared decision-making tool cuts antibiotic use

Patients are much less likely to take antibiotics for an acute respiratory infection if they consult a family doctor who has been trained in shared decision-making, report researchers from Canada.

2 Aug 2012

Shampoo effective for pruritus relief in dogs

Shampooing dogs with pruritus is an effective method to reduce symptoms even if the shampoo does not contain any active ingredients, report researchers in Veterinary Record.

1 Aug 2012

OrPro to advance development of ORP-100 for treatment of cystic fibrosis

OrPro Therapeutics, Inc. today announced that the company has been awarded a National Heart, Lung and Blood Institute Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

31 Jul 2012

InSite Vision second quarter total revenues decrease to $1.8 million

InSite Vision Incorporated today reported financial results for the quarter ended June 30, 2012.

31 Jul 2012

DECISION+2 can reduce antibiotic use for acute respiratory infections

A training tool that helps physicians involve patients in decision-making can reduce the use of antibiotics for acute respiratory infections, according to a study published in CMAJ (Canadian Medical Association Journal).

31 Jul 2012

Combined approach reduces SSIs by 33% in patients after colorectal procedures

A surgical patient safety program that combines three components-accurate outcome measurement, support of hospital leadership, and engaged frontline providers-reduces surgical site infections (SSIs) by 33 percent in patients who undergo colorectal procedures, according to a new study published in the August issue of the Journal of the American College of Surgeons.

30 Jul 2012

TB combination drug: an interview with Mel Spigelman, MD, CEO and President of TB Alliance

TB is a leading global killer. It is the second leading infectious disease in the world, behind HIV. TB is spread through the air, so it can affect anyone, but has its worst impact on impoverished communities and those people with HIV.

27 Jul 2012

Malaria misdiagnosis: an interview with Dr Toby Leslie

Malaria is caused by a multi-staged parasite which is transmitted by the bite of infected female anopheles mosquitoes. It affects millions of people and kills more than 500,000 people throughout the world every year.

26 Jul 2012

Malaria commonly misdiagnosed and mistreated in Afghanistan

Findings published in the BMJ suggest that malaria is being significantly misdiagnosed in Afghanistan, with many patients with fever alone being given antimalarial drugs and antibiotics despite having negative laboratory results for the disease.

25 Jul 2012

WASC accredits Cedars-Sinai PhD program in biomedical sciences and translational medicine

The Graduate Program in Biomedical Sciences and Translational Medicine at Cedars-Sinai has been accredited by the Western Association of Schools and Colleges, an affirmation that the PhD-awarding educational effort meets the most rigorous standards of higher learning.

25 Jul 2012

New combination therapy for TB shows promise in Phase II study

"Results from a groundbreaking trial of three drugs given in combination -- one of them completely new and one not yet licensed for this use -- killed more than 99 percent of patients' [tuberculosis (TB)] bacteria after two weeks of treatment," and the combination "appears to be equally effective on drug-resistant TB," the Guardian reports.

25 Jul 2012

Malaria misdiagnosis in parts of Asia

Substantial overdiagnosis and mistreatment of malaria is evident in south and central Asia, warns a study published on bmj.com today.

25 Jul 2012

Novel combination drug regimen could be more effective than existing treatments for TB

A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet.

24 Jul 2012

TB combination drug trials progress

A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet. These results add to a growing body of evidence that the new regimen could reduce treatment by more than a year for some patients.

24 Jul 2012

Experts examine host recognition of Staphylococcus and E.coli bacteria

We are surrounded by bacteria, viruses, fungi and parasites. The fact that we nevertheless do not fall prey to infections is thanks to certain cellular sensor molecules such as toll-like receptors (TLR), which recognize the molecular structure of pathogens and intercede by ensuring an often completely unnoticeable elimination of the invaders. Their immune-activating abilities were only detected in 1998, a discovery which was awarded with the Nobel Prize

21 Jul 2012

New class of chemically produced antimicrobial agents could become future infection treatment alternative

The World Health Organization (WHO) has named antimicrobial resistance one of the most important threats to human health. We therefore need to find new compounds that can be used as future alternatives to conventional antibiotics.

20 Jul 2012